Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.

Uta SchillingAndrea HenrichClemens MuehlanAndreas KrauseJasper DingemanseMike Ufer

Published in: Clinical drug investigation (2021)

Daridorexant does not impair cardiac repolarization evidenced by absence of relevant QT prolongation at therapeutic and supratherapeutic doses. Clinical Trials Registration ID: NCT04250506.

Keyphrases

drug induced
clinical trial
left ventricular
randomized controlled trial
heart failure
open label
cone beam